MBX news

MBX Biosciences initiated the Phase 3 oPTimize trial for once-weekly canvuparatide in hypoparathyroidism; the initiative positions the biotech firm to vie for a potential best-in-class designation in the endocrine space.

MBX Biosciences reported Q2 results highlighting progress on canvuparatide and MBX 4291 in the obesity pipeline with a robust cash balance.

MBX announced sustained one-year efficacy data for once-weekly canvuparatide in chronic hypoparathyroidism, with a 57% responder rate and high 90% retention. The company remains on track to initiate Phase 3 pivotal trials in Q3 2026, supporting advancement toward commercialization of this potential …